Managlinat dialanetil (MB06322) is an orally bioavailable inhibitor of fructose 1,6-bisphosphatase (FBPase) for the treatment of type 2 diabetes[1] [2].
Managlinat dialanetil dose-dependently inhibits GNG as well as lower basal and postprandial blood glucose levels in Zucker diabetic fatty (ZDF) rats after oral administration[1].
[1]. Wang Y, et al. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2007 Oct;8(10):849-58.
















